Google
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
EYENOVIA, INC. |
Market Closed -
Other stock markets
|
|
5-day change | 1st Jan Change | |
| 1.430 USD | +0.70% | +5.93% | -12.27% | |
| Nov. 13 | Eyenovia, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 | CI |
| Nov. 13 | Transcript : Eyenovia, Inc., Q3 2023 Earnings Call, Nov 13, 2023 | CI |
Financials (USD)
| Sales 2023 * | 552,250 | Sales 2024 * | 2.64 M | Capitalization | 63.09 M |
|---|---|---|---|---|---|
| Net income 2023 * | -26.00 M | Net income 2024 * | -33.00 M | EV / Sales 2023 * | 114x |
| Net cash position 2023 * | - | Net cash position 2024 * | - | EV / Sales 2024 * | 23,9x |
| P/E ratio 2023 * | -2,12x | P/E ratio 2024 * | -1,76x | Employees | 41 |
| Yield 2023 * | - | Yield 2024 * | - | Free-Float | 81.59% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +0.70% | ||
| 1 week | +5.93% | ||
| Current month | +0.70% | ||
| 1 month | +1.42% | ||
| 3 months | -26.67% | ||
| 6 months | -53.87% | ||
| Current year | -12.27% |
1 week
1.35
1.54
1 month
1.101.54
Current year
1.055.85
1 year
1.055.85
3 years
1.057.72
5 years
1.057.72
10 years
1.0510.74
| Managers | Title | Age | Since |
|---|---|---|---|
Michael Rowe
CEO | Chief Executive Officer | 61 | 2018 |
| Founder | 49 | 2014 | |
John Gandolfo
DFI | Director of Finance/CFO | 62 | 2017 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ellen Strahlman
BRD | Director/Board Member | 65 | - |
Michael Rowe
CEO | Chief Executive Officer | 61 | 2018 |
| Founder | 49 | 2014 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.37% | 5 M€ | -13.59% | ||
| 0.01% | 678 M€ | -2.75% | ||
| 0.00% | 8,183 M€ | +8.04% | ||
| 0.00% | 620 M€ | +8.31% | - | |
| 0.00% | 7 M€ | -2.29% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 23-12-01 | 1.430 | +0.70% | 188,660 |
| 23-11-30 | 1.420 | 0.00% | 299,173 |
| 23-11-29 | 1.420 | -2.74% | 320,143 |
| 23-11-28 | 1.460 | -0.68% | 303,829 |
| 23-11-27 | 1.470 | +8.89% | 387,257 |
Delayed Quote Nasdaq, December 01, 2023 at 04:00 pm EST
More quotes
Eyenovia, Inc. is a pre-commercial ophthalmic technology company. The Company is developing the Optejet delivery system both for use in combination with its own drug-device therapeutics and for out-licensing for use in combination with therapeutics for additional indications. Its product candidates include MicroLine (for presbyopia), MicroPine (for progressive myopia) and Mydcombi (for mydriasis). MicroLine is its microdosed version of pilocarpine, a well-understood ophthalmic medication that can dose-dependently induce miosis, or a contraction of the pupil. MicroPine is a topical treatment for progressive myopia, a back-of-the-eye disease. MicroPine program involves the development of a micro-formulation of atropine ophthalmic solution for reduction of myopia progression in children. Mydcombi is a fixed combination micro-formulation product candidate for mydriasis (eye dilation). Its fixed combination product candidate has been developed to facilitate efficient pupil dilation.
Sector
Pharmaceuticals
Calendar
2024-03-26
- Q4 2023 Earnings Release (Projected)
Trading Rating :
Investor Rating :
ESG Refinitiv :
-
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.430USD
Average target price
11.67USD
Spread / Average Target
+715.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.27% | 63 M $ | |
| +59.64% | 525 B $ | |
| +48.98% | 454 B $ | |
| -10.34% | 381 B $ | |
| -6.75% | 262 B $ | |
| -11.26% | 253 B $ | |
| -17.52% | 221 B $ | |
| +2.14% | 202 B $ | |
| -9.09% | 200 B $ | |
| -43.58% | 163 B $ |
